# Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study

> **NCT06950671** · — · NOT_YET_RECRUITING · sponsor: **Rahma Esam Salama Esawi** · enrollment: 1 (estimated)

## Conditions studied

- Breast Cancer Stage I
- Breast Cancer Stage II
- Breast Cancer Stage III
- Breast Cancer Invasive

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06950671
- **Lead sponsor:** Rahma Esam Salama Esawi
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2028-09-15
- **Final completion:** 2029-09
- **Target enrollment:** 1 (ESTIMATED)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06950671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06950671, "Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06950671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*